BPC-157 Dosage Guide: Reported Ranges, µg Conversions & Reconstitution
BPC-157 amounts reported in the literature, microgram-to-insulin-unit conversions for a 5 mg vial, oral vs reconstituted formats, and storage.
By PX1 Research Team · August 4, 2026
BPC-157 amounts reported in research
BPC-157 is a synthetic pentadecapeptide derived from a gastric protein. Rodent studies typically report ranges of 10 µg/kg per administration, which most human-equivalent conversions in the literature translate into the 200–500 µg range, commonly split into one or two administrations per day across 2–6 week study windows.
| Format | Commonly reported range |
|---|---|
| Reconstituted solution | 250–500 µg per administration |
| Oral / capsule studies | 250–500 µg daily |
Reconstitution reference (5 mg vial)
5 mg in 2.5 mL bacteriostatic water = 2 mg/mL:
| Target | Volume | Insulin units |
|---|---|---|
| 250 µg | 0.125 mL | 12.5 |
| 500 µg | 0.25 mL | 25 |
| 1 mg | 0.50 mL | 50 |
BPC-157 and KPV / TB-500 in combined study designs
Study designs frequently pair BPC-157 with TB-500 (repair models) or with KPV and larazotide (gut-barrier models). PX1 supplies both a BPC-157 capsule and a BPC-157 + KPV + larazotide gut blend for protocols that call for an oral route.
Storage
Lyophilized BPC-157 is room-temperature stable in a sealed vial; refrigerate after reconstitution and use within roughly 28 days when bacteriostatic water is the diluent.
Product page: BPC-157.
All figures below are reported from published laboratory literature and are provided for informational and laboratory-research context only. PX1 Research supplies compounds for laboratory and research use only — not for human or veterinary use.